$0.89 EPS Expected for MEDNAX Inc (MD) This Quarter

Analysts forecast that MEDNAX Inc (NYSE:MD) will report earnings of $0.89 per share for the current quarter, according to Zacks. Eight analysts have issued estimates for MEDNAX’s earnings, with estimates ranging from $0.83 to $1.00. MEDNAX reported earnings of $1.07 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 16.8%. The company is expected to announce its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that MEDNAX will report full year earnings of $3.54 per share for the current financial year, with EPS estimates ranging from $3.28 to $3.78. For the next fiscal year, analysts expect that the business will post earnings of $3.94 per share, with EPS estimates ranging from $3.39 to $4.66. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.63 by ($0.05). MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. The company had revenue of $851.20 million during the quarter, compared to analyst estimates of $906.35 million. During the same period in the prior year, the business posted $0.89 EPS. MEDNAX’s revenue for the quarter was down .2% compared to the same quarter last year.

Several research firms recently commented on MD. Zacks Investment Research cut MEDNAX from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Citigroup set a $36.00 price target on MEDNAX and gave the company a “buy” rating in a report on Friday, May 3rd. Jefferies Financial Group cut their price target on MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a report on Thursday, April 11th. Mizuho reaffirmed a “hold” rating and issued a $38.00 price target on shares of MEDNAX in a report on Monday, January 28th. Finally, Credit Suisse Group cut their price target on MEDNAX from $44.00 to $42.00 and set an “outperform” rating for the company in a report on Wednesday, February 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $40.55.

In other MEDNAX news, Director Md Pascal J. Goldschmidt sold 3,300 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $30.40, for a total transaction of $100,320.00. Following the completion of the sale, the director now owns 20,821 shares of the company’s stock, valued at $632,958.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Dominic J. Andreano sold 1,289 shares of the firm’s stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $36.22, for a total value of $46,687.58. Following the sale, the senior vice president now directly owns 69,069 shares of the company’s stock, valued at approximately $2,501,679.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,779 shares of company stock valued at $897,454. 3.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Hawaiian Bank boosted its position in shares of MEDNAX by 5.4% during the fourth quarter. First Hawaiian Bank now owns 12,571 shares of the company’s stock worth $415,000 after buying an additional 643 shares during the period. Canada Pension Plan Investment Board boosted its position in shares of MEDNAX by 56.9% during the fourth quarter. Canada Pension Plan Investment Board now owns 211,334 shares of the company’s stock worth $6,973,000 after buying an additional 76,600 shares during the period. Norges Bank purchased a new position in shares of MEDNAX during the fourth quarter worth $34,138,000. Flinton Capital Management LLC boosted its position in shares of MEDNAX by 11.2% during the fourth quarter. Flinton Capital Management LLC now owns 120,360 shares of the company’s stock worth $3,972,000 after buying an additional 12,138 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its position in shares of MEDNAX by 13.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,270,910 shares of the company’s stock worth $41,940,000 after buying an additional 151,320 shares during the period. Institutional investors and hedge funds own 93.46% of the company’s stock.

Shares of NYSE:MD traded down $0.53 during midday trading on Friday, hitting $26.70. The company had a trading volume of 1,205,900 shares, compared to its average volume of 1,185,539. MEDNAX has a twelve month low of $25.47 and a twelve month high of $48.77. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.55 and a current ratio of 2.55. The stock has a market cap of $2.47 billion, a PE ratio of 7.61, a P/E/G ratio of 1.09 and a beta of 0.59.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.